WebFeb 8, 2024 · atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced it has received approval for the start of the second phase of its ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial. WebatHeart Medical 625 Follower:innen auf LinkedIn. Minimal footprint, more options for the future atHeart Medical was founded to establish the first transcatheter septal occluder with a metal-free frame, as the new standard of care for atrial septal defects. We have initiated the U.S. FDA approved ASCENT-ASD pivotal trial in the United States and internationally to …
AtHeart Leaves Nothing Behind with ASD Occluder
WebFeb 8, 2024 · ASCENT ASD U.S. IDE Trial is a prospective, single-arm study is evaluating the safety and efficacy of the reSept™ ASD Occluder, the first occluder with a metal-free, … WebOct 19, 2024 · Prospective, three-stage, single arm, multi-site, clinical investigation evaluating the safety and efficacy of the reSept ASD Occluder in treating clinically … shop push sweeper
Safety and Efficacy Study of reSept ASD Occluder for Treating …
WebEvaluation of the safety and efficacy of the reSept ASD Occluder to treat patients with clinically significant secundum atrial septal defect. Trial with. CARAG, LLC. Ages. 84 years … WebApr 20, 2024 · The reSept ASD Occluder is an occluder with a metal-free, bioresorbable frame. The implant is designed to overcome the limitations of occluders by reducing the … WebApr 20, 2024 · ASCENT-ASD is an FDA-approved investigational device exemption trial that will evaluate the safety and efficacy of the reSept ASD occluder for treating patients with … shop purses videos